Medical Information | Multiple Myeloma Hub
Online resource for healthcare professionals, providing information, news & support relating to multiple myeloma
Online resource for healthcare professionals, providing information, news & support relating to multiple myeloma
During the EHA-EBMT 6th European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Paola Neri, University of Calgary, Calgary, CA. We asked, What factors…
Here, we summarize a report published by Guerrero et al. in Blood on predictors of unsustainable MRD-negativity in patients with multiple myeloma who are eligible…
MISSOURI (KSNF) — One university in the Show-Me State receives high marks on a global scale. Washington University in St. Louis (WUSTL) is ranked 8th…
Here, we summarize a retrospective study published by Lery et al. in Journal of the American Academy of Dermatology on the dermatological toxicities associated with…
On March 20, 2024, the European Commission granted approval to ide-cel for the treatment of triple-class-exposed RRMM with two or more prior therapies, including an…
Study in Blood dissecting the role of NFκB signaling effectors in MPN disease biology Stephen T. Oh, MD, PhD, Co-Chief and Associate Professor of Medicine,…
Here, we summarize a study published by Nieto et al. in American Journal of Hematology on the safety and efficacy of high-dose panobinostat combined with…
Here, we summarize a post hoc analysis investigating the effects of refractoriness to standard-dose prior alkylators on the effectiveness of melflufen + dexamethasone on a…
We summarize key results from the phase II GMMG-CONCEPT trial investigating transplant-eligible and non-transplant-eligible patients with newly diagnosed high-risk multiple myeloma treated with isatuximab, carfilzomib,…
We summarize key results from the phase II GMMG-CONCEPT trial investigating transplant-eligible and non-transplant-eligible patients with newly diagnosed high-risk multiple myeloma treated with isatuximab, carfilzomib,…